KORU Medical Systems presented data at the 2024 PODD Conference showcasing nurse preference for the KORU FreedomEdge® Infusion System in administering subcutaneous oncology infusions. The study, conducted across six Danish hospitals, involved 33 nurses administering over 3,000 infusions of an oncology drug exceeding 10mL in volume, with an average administration time of around 10 minutes. It aimed to evaluate time spent with patients, nurses’ comfort levels, and overall nurse preference when comparing manual syringe administration with the FreedomEdge® system’s mechanical pump approach.
The increasing use of large-volume subcutaneous oncology drugs presents workflow challenges in clinical settings due to the extended hands-on administration time required for manual syringe pushes. This necessitates continuous manual pressure on syringes containing viscous drugs for approximately 10 minutes. Subcutaneous delivery of previously intravenous biologics is a growing trend among oncology pharmaceutical manufacturers. Five such drugs, with volumes greater than 5mL, are approved for in-clinic administration by healthcare professionals, accounting for an estimated one million global infusions.
Subcutaneous administration offers several advantages, including simplified treatment protocols, reduced strain on hospitals, and improved patient quality of life. The continued development of subcutaneous drug therapies creates a significant opportunity for drug delivery solutions like the KORU FreedomEdge® system, which offers an alternative to manual administration. The study results indicate a strong nurse preference for the FreedomEdge® system. KORU Medical anticipates filing for FDA clearance of its system with an oncology biologic in 2025.
KORU Medical specializes in developing, manufacturing, and commercializing innovative, patient-centric, large-volume subcutaneous infusion solutions. Their FREEDOM Syringe Infusion System encompasses the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets™. Initially FDA-cleared in 1994, the Freedom System caters to home self-administration by patients and ambulatory infusion center delivery by healthcare professionals. KORU Medical’s Novel Therapies business supports biopharmaceutical companies with products for feasibility and clinical trials during drug development. They also offer customization of the Freedom System for clinical and commercial use across various drug categories.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
